Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
109.42
-0.69 (-0.63%)
Jun 4, 2025, 1:35 PM - Market open
Axsome Therapeutics Stock Forecast
Stock Price Forecast
According to 16 professional analysts, the 12-month price target for Axsome Therapeutics stock ranges from a low of $105 to a high of $216. The average analyst price target of $171.13 forecasts a 56.40% increase in the stock price over the next year.
Price Target: $171.13 (+56.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 7 | 6 | 6 | 7 | 7 | 7 |
Buy | 7 | 8 | 8 | 8 | 8 | 9 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 14 | 14 | 14 | 15 | 15 | 16 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Oppenheimer | Oppenheimer | Buy Initiates $185 | Buy | Initiates | $185 | +69.07% | Jun 3, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $180 | Strong Buy | Reiterates | $180 | +64.50% | May 22, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $180 | Strong Buy | Maintains | $200 → $180 | +64.50% | May 7, 2025 |
Wells Fargo | Wells Fargo | Buy Maintains $160 → $165 | Buy | Maintains | $160 → $165 | +50.80% | May 6, 2025 |
Baird | Baird | Buy Maintains $160 → $162 | Buy | Maintains | $160 → $162 | +48.05% | May 6, 2025 |
Financial Forecast
Revenue This Year
629.31M
from 385.69M
Increased by 63.16%
Revenue Next Year
1.01B
from 629.31M
Increased by 60.81%
EPS This Year
-3.63
from -5.99
EPS Next Year
1.68
from -3.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 696.9M | 1.2B | 2.0B | ||
Avg | 629.3M | 1.0B | 1.6B | ||
Low | 569.6M | 806.5M | 1.1B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 80.7% | 92.0% | 95.4% | ||
Avg | 63.2% | 60.8% | 54.3% | ||
Low | 47.7% | 28.2% | 13.2% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.94 | 5.26 | 16.09 | ||
Avg | -3.63 | 1.68 | 10.16 | ||
Low | -4.36 | -2.33 | 2.25 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 858.9% | ||
Avg | - | - | 505.5% | ||
Low | - | - | 34.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.